Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:APVO NASDAQ:CLRB NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.68-6.5%$0.77$0.38▼$115.57$7.68M0.711.79 million shs131,849 shsAPVOAptevo Therapeutics$2.68-3.9%$3.68$2.65▼$381.10$2.11M5.64146,676 shs85,754 shsCLRBCellectar Biosciences$4.72-2.5%$7.43$4.36▼$68.70$8.76M0.42117,034 shs84,512 shsTRAWTraws Pharma$1.46-5.2%$1.56$0.97▼$19.44$8.57M1.1470,741 shs64,288 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-6.54%-13.94%-19.08%+35.59%-99.45%APVOAptevo Therapeutics-3.94%-12.42%-11.84%-73.23%-99.98%CLRBCellectar Biosciences-2.48%-7.27%-0.21%-41.88%-92.68%TRAWTraws Pharma-5.19%-7.59%0.00%+2.82%+145,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma3.3348 of 5 stars3.55.00.00.00.61.71.9APVOAptevo Therapeutics1.8692 of 5 stars3.53.00.00.00.00.01.3CLRBCellectar Biosciences2.6295 of 5 stars3.25.00.00.00.01.71.3TRAWTraws PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0052,864.54% UpsideAPVOAptevo Therapeutics 3.00Buy$219,040.008,173,034.33% UpsideCLRBCellectar Biosciences 2.33Hold$375.007,844.92% UpsideTRAWTraws Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, AEON, CLRB, and TRAW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AAPVOAptevo Therapeutics$3.11M0.65N/AN/A$65.21 per share0.04CLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/ATRAWTraws Pharma$230K35.29N/AN/A($8.66) per share-0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.123.78N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)APVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)CLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)TRAWTraws Pharma-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)Latest APVO, AEON, CLRB, and TRAW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/AAPVOAptevo Therapeutics-$83.20N/AN/AN/AN/AN/A8/13/2025Q2 2025CLRBCellectar Biosciences-$3.70N/AN/AN/AN/AN/A8/11/2025N/AAEONAEON Biopharma-$11.51N/AN/AN/AN/AN/A5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22APVOAptevo TherapeuticsN/A0.670.67CLRBCellectar BiosciencesN/A2.472.47TRAWTraws PharmaN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%APVOAptevo Therapeutics8.06%CLRBCellectar Biosciences16.41%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%APVOAptevo Therapeutics0.01%CLRBCellectar Biosciences5.04%TRAWTraws Pharma13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableAPVOAptevo Therapeutics50760,000756,000Not OptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionableTRAWTraws Pharma175.56 million4.81 millionOptionableAPVO, AEON, CLRB, and TRAW HeadlinesRecent News About These CompaniesTRAW - Traws Pharma Inc Sustainability - MorningstarJuly 16, 2025 | morningstar.comMCooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws PharmaJuly 8, 2025 | msn.comTraws Pharma announces chief financial officer transitionJuly 5, 2025 | uk.investing.comTraws Pharma, Inc. (TRAW) Income Statement - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comTraws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsJune 30, 2025 | finanznachrichten.deTraws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDAJune 30, 2025 | quiverquant.comQTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsJune 30, 2025 | globenewswire.comTraws Pharma Announces Promising Clinical Data for Rigosertib in Rare CancerJune 5, 2025 | msn.comTraws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug RigosertibJune 3, 2025 | globenewswire.comTraws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic PreparednessMay 27, 2025 | globenewswire.comTraws Pharma Unveils New Strategic Antiviral FocusMay 19, 2025 | tipranks.comTraws Pharma Highlights Q1 2025 Financial Progress and Antiviral DevelopmentsMay 18, 2025 | msn.comTraws Pharma Reports First Quarter 2025 Results and Business HighlightsMay 15, 2025 | globenewswire.comTraws Pharma Appoints New Chairman Amid Leadership ChangesApril 18, 2025 | tipranks.comThe Escalator: HHS, Spectrum Science, Alvotech and moreApril 3, 2025 | mmm-online.comMTraws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID ProgramsApril 2, 2025 | msn.comTraws Pharma reports FY24 EPS ($35.21)April 1, 2025 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Virtual Investor Event TranscriptApril 1, 2025 | seekingalpha.comTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, AEON, CLRB, and TRAW Company DescriptionsAEON Biopharma NASDAQ:AEON$0.68 -0.05 (-6.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.68 0.00 (-0.25%) As of 08/1/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Aptevo Therapeutics NASDAQ:APVO$2.68 -0.11 (-3.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.69 +0.01 (+0.37%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Cellectar Biosciences NASDAQ:CLRB$4.72 -0.12 (-2.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.76 +0.04 (+0.74%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Traws Pharma NASDAQ:TRAW$1.46 -0.08 (-5.19%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.50 +0.04 (+2.67%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
